期刊
CANCER BIOLOGY & THERAPY
卷 10, 期 9, 页码 843-857出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.10.9.13738
关键词
chemotherapy; resistance; targeted therapy; RNAi screen; integrative biology; DNA damage; synthetic lethality
类别
资金
- Genentech
- NIH [CA153077, CA120091, CA63366, CA113342, CA-06927]
- Fox Chase Cancer Center Head and Neck Cancer Keystone
- Pew Charitable Trust
In recent years, oncologists have begun to conclude that chemotherapy has reached a plateau of efficacy as a primary treatment modality, even if toxicity can be effectively controlled. Emerging specific inhibitors of signaling and metabolic pathways (i.e., targeted agents) contrast with traditional chemotherapy drugs in that the latter primarily interfere with the DNA biosynthesis and the cell replication machinery. In an attempt to improve on the efficacy, combination of targeted drugs with conventional chemotherapeutics has become a routine way of testing multiple new agents in early phase clinical trials. This review discusses the recent advances including integrative systematic biology and RNAi approaches to counteract the chemotherapy resistance and to buttress the selectivity, efficacy and personalization of anticancer drug therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据